In 2004 the company was purchased from the original owners in an employee buyout. Since then it has expanded sales and distribution both domestically and in international markets. Today UreSil is experiencing a significant increase in market demand that accompanies an expansion of GPO and IDN relationships. UreSil’s sales force consists of over eighty sales representatives in the continental US and over one hundred twenty additional representatives throughout all of the major world markets.

Our product focus has historically been in the area of interventional radiology and vascular surgery. As we continue a rapid growth trend within these markets, we have and are expanding our reach to include centesis procedures, interventional vascular and interventional cardiac procedures as these are a natural fit for our expertise and resources.